Then, the smart synergism of the abundant TAAs with adjuvant OMVs boosted the maturation of DCs and activated the antigen presentation by MHC-I molecules on resident CD8+ DCs, finally evoking robust tumor-specific immunity that suppressed the established bilateral tumors as well as prevented the tumor metastasis and recurrence. Here, CD8A is linked to neoplasm.